CoChat

Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment

Open access
Lecoutey, Cédric, Hedou, Damien, Freret, Thomas, Giannoni, Patrizia, Gaven, Florence, Since, Marc, Bouet, Valentine, Ballandonne, Céline, Corvaisier, Sophie, Malzert Fréon, Aurélie, Mignani, Serge, Cresteil, Thierry, Boulouard, Michel, Claeysen, Sylvie, Rochais, Christophe, Dallemagne, Patrick · 2014 · Proceedings of the National Academy of Sciences
Cited by 133

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Significance: Targeting more than one molecular cause implied in the pathogenesis of Alzheimer’s disease (AD) with a sole drug is considered a promising challenge, because it may address the numerous failures that recently occurred during clinical trials that were conducted in this area. Donecopride has been designed by us as a multitarget-directed ligand, targeting both serotonin subtype 4 receptor and acetylcholinesterase with excellent in vitro activities. The latter seems able to not only restore the cholinergic neurotransmission altered in AD but also, promote the secretion of a neurotrophic protein that is detrimental to the neurotoxic amyloid-β peptide. With its excellent drugability, donecopride further displayed significant procognitive effects in mice and generated a promising lead for a previously unidentified approach in AD treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.1410315111

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 133

Metadata

Authors
Lecoutey, C., Hedou, D., Freret, T., Giannoni, P., Gaven, F., Since, M., Bouet, V., Ballandonne, C., Corvaisier, S., Malzert Fréon, A., Mignani, S., Cresteil, T., Boulouard, M., Claeysen, S., Rochais, C., & Dallemagne, P.
Venue
Proceedings of the National Academy of Sciences
Published
2014-08-25
Volume
111
Issue
36
Pages
E3825-30
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2013121971
Cited by
133
References
6
FWCI
6.93
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. https://app.cochat.ai/papers/10.1073/pnas.1410315111
The paper
Lecoutey, C., Hedou, D., Freret, T., Giannoni, P., Gaven, F., Since, M., Bouet, V., Ballandonne, C., Corvaisier, S., Malzert Fréon, A., Mignani, S., Cresteil, T., Boulouard, M., Claeysen, S., Rochais, C., & Dallemagne, P. (2014). Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer's disease treatment. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1410315111

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.